ClinicalTrials.gg
CompletedNCT04620733Updated Sep 5, 2024Results posted

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

A Phase 3 interventional study of Seladelpar 10 mg and Placebo in Primary Biliary Cholangitis, sponsored by Gilead Sciences. Completed at 134 sites in 26 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
193
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences — 2 open to participants now, 3 under way, 2 of them phase 3. Liver Cirrhosis, Biliary · Gilead Sciences.

Enrollment
4th of 10
193 · median 126
Started
2021
with 1 other
Phase 3
5 of 10
1 open now
Registered
6th of 10
by date

Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, this one is the 4th largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 3, and was the 6th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

2 of the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, or all of them as a file.
02

Study summary

The purposes of this study are to evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo.

The study also checked the effect of treatment on the symptoms of PBC, including pruritus.

03

Conditions studied

  • Primary Biliary Cholangitis

Keywords

  • Primary Biliary Cholangitis (PBC)
  • PBC
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have given written (signed and dated) and any authorizations required by local law.
  • Male or female with a definitive diagnosis of primary biliary cholangitis (PBC).
  • Ursodeoxycholic acid (UDCA) for the past 12 months (stable dose for >3 months prior to screening) or intolerant to UDCA (last dose of UDCA >3 months prior to screening).
  • Laboratory parameters measured by the Central Laboratory at screening:

    • Alkaline phosphatase (ALP) ≥1.67× (upper limit of normal)
    • (AST) ≤3× ULN
    • Alanine aminotransferase (ALT) ≤3× ULN
    • Total ≤2× ULN
    • Estimated (eGFR) >45 mL/min/1.73 m\^2 (calculated by the Modification of Diet in Renal Disease study equation).
    • (INR) below 1.1× ULN (For individuals on anticoagulation therapy, INR must be maintained in the range required for prophylaxis for their specific disease).
    • count ≥100 ×10\^3/µL.
  • Females of must use at least 1 barrier and a second effective birth control method during the study and for at least 90 days after the last dose. Male individuals who are sexually active with female partners of reproductive potential must use barrier contraception, and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose.

Key Exclusion Criteria:

  • Previous exposure to seladelpar (MBX-8025).
  • A medical condition other than PBC that, in the investigator's opinion, would preclude full participation in the study (e.g., cancer) or confound its results (e.g., Paget's disease, any active infection).
  • Advanced PBC as defined by the Rotterdam criteria (albumin below the lower limit of normal and total bilirubin above 1.0 × ULN).
  • Presence of hepatic decompensation, including the following:

    • History of liver transplantation, current placement on liver transplantation list, or current Model for End-Stage Liver Disease (MELD) score ≥12. For individuals on anticoagulation medication, evaluation of the baseline INR, in concert with their current dose adjustments of their anticoagulant medication, will be taken into account when calculating the MELD score. This will be done in consultation with the medical monitor.
    • Complications of portal hypertension, including known esophageal varices, history of variceal bleeds or related interventions (e.g., transjugular intrahepatic portosystemic shunt placement), ascites, and hepatic encephalopathy.
    • Cirrhosis with complications, including history or presence of spontaneous bacterial peritonitis, hepatocellular carcinoma, or hepatorenal syndrome.
  • Other chronic liver diseases:

    • Current features of hepatitis (AIH) as determined by the investigator based on immunoserology, liver biochemistry, or historic confirmed liver histology.
    • PSC determined by the presence of diagnostic cholangiographic findings.
    • History or clinical evidence of alcoholic liver disease.
    • History or clinical evidence of alpha-1-antitrypsin deficiency.
    • History of confirmed nonalcoholic steatohepatitis (NASH).
    • History or evidence of Gilbert's syndrome with elevated total bilirubin.
    • History or evidence of hemochromatosis.
    • , defined as the presence of hepatitis B surface antigen.
    • , defined as the presence of hepatitis C virus ribonucleic acid.
    • History, evidence, or high suspicion of hepatobiliary based on imaging, screening laboratory values, and/or clinical symptoms.
  • Known history of (HIV) or positive antibody test at screening
  • Clinically important alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to quantify alcohol intake reliably.
  • History of malignancy diagnosed or treated, actively or within 2 years, or ongoing evaluation for malignancy; localized treatment of squamous or noninvasive basal cell skin cancers and cervical carcinoma in situ is allowed if appropriately treated prior to screening.
  • Treatment with obeticholic acid (OCA) or fibrates (e.g., bezafibrate, fenofibrate, elafibranor, lanifibranor, pemafibrate, saroglitizar) 6 weeks prior to screening.
  • Treatment with colchicine, methotrexate, azathioprine, or long-term systemic (>2 weeks) during 2 months prior to screening
  • Treatment with anti-pruritic drugs (e.g., cholestyramine, naltrexone, rifampicin, sertraline, or any experimental approach) must be on a stable dose within 1 month prior to screening
  • Treatment with any other therapy or device within 30 days or within 5 half-lives, whichever is longer, prior to screening
  • For females, pregnancy or breastfeeding.
  • Any other condition(s) that would compromise the safety of the individual or compromise the quality of the clinical study, as judged by the investigator.
  • therapies.
  • Other medications that effect liver or gastrointestinal (GI) functions, such as absorption of medications or the roux-en-y gastric bypass procedure, may be prohibited and should be discussed with the medical monitor on a case-by-case basis.
  • Active Coronavirus Disease-2019 (COVID-19) infection during Screening.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
193 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive placebo to match seladelpar, orally, once daily, for a duration of up to 12 months.

    Drug: Placebo

  • Experimental
    Seladelpar

    Participants will receive seladelpar 10 mg (or 5 mg down-titrated, for those participants who met specific safety monitoring criteria or had tolerability issues), orally, once daily, for a duration of up to 12 months.

    Drug: Seladelpar 10 mg · Drug: Seladelpar 5 mg

Interventions

  • Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months

  • DrugPlacebo

    One capsule daily for double-blind period, for a duration of up to 12 months

  • If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Response Criteria for the Composite Endpoint of ALP <1.67 × Upper Limit of Normal (ULN), ≥15% Reduction in ALP, and Total Bilirubin ≤ 1.0× ULN at Month 12

    Percentages were rounded-off.

    Time frame: Month 12

  2. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    Percentages were rounded-off.

    Time frame: First dose date up to last dose plus 30 days (up to 13.4 months)

  3. Percentage of Participants With Shift of ≥ 2 CTCAE Grades From Baseline in Treatment-emergent Laboratory Abnormalities Related to Hematology and Select Liver Biochemistry

    Treatment-emergent graded laboratory abnormalities were defined as values that increase at least 2 toxicity grade from baseline at any time post baseline. The laboratory abnormalities were graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening laboratory abnormality. The data is reported for shift of ≥ 2 grades from baseline in values for hematology and select liver biochemistry. Hematology includes parameters like RBCs, (erythrocytes), hemoglobin, hematocrit, platelets, WBC, WBC differentials (absolute and percentage) including basophils, neutrophils, lymphocytes, eosinophils, and monocytes, etc. Biochemistry included select liver function tests like blood bilirubin, gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Percentages were rounded-off.

    Time frame: First dose date up to last dose (up to 13.4 months)

Secondary outcomes

  1. Percentage of Participants With ALP ≤1.0× ULN at Month 12

    Percentages were rounded-off.

    Time frame: Month 12

  2. Change From Baseline in Weekly Averaged Pruritus Numerical Rating Scale (NRS) in Participants With NRS ≥ 4 at Month 6

    Pruritus NRS is used to rate the intensity of the itching experienced by the participants in the past 24 hours from no itching to worst possible itching by selecting a number from 0 to 10 on Itch Scale. Zero means no itching and 10 means worst imaginable itching.

    Time frame: Baseline, Month 6

07

Results

Posted Jul 25, 2024

Participant flow

Participants were enrolled at study sites in the Asia Pacific, Europe, Latin America, and North America.

Participant flow — Overall Study
MilestonePlaceboSeladelpar
Started65128
Completed57117
Not completed811
Withdrew: Adverse event43
Withdrew: Withdrawal by subject25
Withdrew: Lost to follow-up11
Withdrew: Protocol deviation11
Withdrew: Reason not specified01

Outcome measures

PrimaryPercentage of Participants With Response Criteria for the Composite Endpoint of ALP <1.67 × Upper Limit of Normal (ULN), ≥15% Reduction in ALP, and Total Bilirubin ≤ 1.0× ULN at Month 12

Percentages were rounded-off.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Response Criteria for the Composite Endpoint of ALP <1.67 × Upper Limit of Normal (ULN), ≥15% Reduction in ALP, and Total Bilirubin ≤ 1.0× ULN at Month 12
percentage of participantsPlaceboSeladelpar
Percentage of Participants With Response Criteria for the Composite Endpoint of ALP <1.67 × Upper Limit of Normal (ULN), ≥15% Reduction in ALP, and Total Bilirubin ≤ 1.0× ULN at Month 1220.0 (10.3 to 29.7)61.7 (53.3 to 70.1)
Statistical analysis
  • Placebo vs Seladelpar · Cochran-Mantel-Haenszel · p = < 0.0001 (Two-sided p-value for pair-wise comparison was based on the CMH test adjusted for both randomization stratification variables (baseline ALP level: \< 350 U/L and ≥ 350 U/L; baseline Pruritus NRS: \< 4 and ≥ 4).) · Risk difference (rd): 41.7 · 95% CI 27.7 to 53.4
PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

Percentages were rounded-off.

Time frame:
First dose date up to last dose plus 30 days (up to 13.4 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
percentage of participantsPlaceboSeladelpar
TEAEs84.686.7
Serious TEAEs6.27.0
PrimaryPercentage of Participants With Shift of ≥ 2 CTCAE Grades From Baseline in Treatment-emergent Laboratory Abnormalities Related to Hematology and Select Liver Biochemistry

Treatment-emergent graded laboratory abnormalities were defined as values that increase at least 2 toxicity grade from baseline at any time post baseline. The laboratory abnormalities were graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: potentially life-threatening laboratory abnormality. The data is reported for shift of ≥ 2 grades from baseline in values for hematology and select liver biochemistry. Hematology includes parameters like RBCs, (erythrocytes), hemoglobin, hematocrit, platelets, WBC, WBC differentials (absolute and percentage) including basophils, neutrophils, lymphocytes, eosinophils, and monocytes, etc. Biochemistry included select liver function tests like blood bilirubin, gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Percentages were rounded-off.

Time frame:
First dose date up to last dose (up to 13.4 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Shift of ≥ 2 CTCAE Grades From Baseline in Treatment-emergent Laboratory Abnormalities Related to Hematology and Select Liver Biochemistry
percentage of participantsPlaceboSeladelpar
Shift ≥ 2 CTCAE grades in haematology12.314.1
Shift ≥ 2 CTCAE grades in biochemistry6.27.0
SecondaryPercentage of Participants With ALP ≤1.0× ULN at Month 12

Percentages were rounded-off.

Time frame:
Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With ALP ≤1.0× ULN at Month 12
percentage of participantsPlaceboSeladelpar
Percentage of Participants With ALP ≤1.0× ULN at Month 120.0 (0.0 to 0.0)25.0 (17.5 to 32.5)
Statistical analysis
  • Placebo vs Seladelpar · Cochran-Mantel-Haenszel · p = < 0.0001 · Risk difference (rd): 25.0 · 95% CI 18.3 to 33.2Two-sided p-value for pair-wise comparison is based on the Cochran Mantel Haenszel test adjusted for both stratification variables (baseline ALP level: \< 350 U/L and \>= 350 U/L; baseline pruritus NRS: \< 4 and \>= 4).
SecondaryChange From Baseline in Weekly Averaged Pruritus Numerical Rating Scale (NRS) in Participants With NRS ≥ 4 at Month 6

Pruritus NRS is used to rate the intensity of the itching experienced by the participants in the past 24 hours from no itching to worst possible itching by selecting a number from 0 to 10 on Itch Scale. Zero means no itching and 10 means worst imaginable itching.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · score on scale
Change From Baseline in Weekly Averaged Pruritus Numerical Rating Scale (NRS) in Participants With NRS ≥ 4 at Month 6
score on scalePlaceboSeladelpar
Change From Baseline in Weekly Averaged Pruritus Numerical Rating Scale (NRS) in Participants With NRS ≥ 4 at Month 6-1.7 ± 0.41-3.2 ± 0.28
Statistical analysis
  • Placebo vs Seladelpar · MMRM · p = 0.0047 · Least squares (ls) mean difference: -1.5 · 95% CI -2.5 to -0.5Mixed-Effect Model Repeated Measure (MMRM)

Adverse events

Collected over All-cause mortality: Up to 20.6 months; Adverse events: Up to last dose plus 30 days (Up to 13.4 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/65 (0%)4/65 (6.2%)40/65 (61.5%)
Seladelpar0/128 (0%)9/128 (7%)66/128 (51.6%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlaceboSeladelpar
Covid-19Infections and infestations1/651/128
PneumoniaInfections and infestations1/650/128
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/650/128
HeadacheNervous system disorders1/650/128
PresyncopeNervous system disorders1/650/128
Suicide attemptPsychiatric disorders1/650/128
CoagulopathyBlood and lymphatic system disorders0/651/128
Coronary artery diseaseCardiac disorders0/651/128
Duodenal obstructionGastrointestinal disorders0/651/128
Oesophageal varices haemorrhageGastrointestinal disorders0/651/128
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlaceboSeladelpar
Covid-19Infections and infestations9/6523/128
PruritusSkin and subcutaneous tissue disorders10/656/128
Upper respiratory tract infectionInfections and infestations6/651/128
HeadacheNervous system disorders1/6510/128
NasopharyngitisInfections and infestations5/657/128
PharyngitisInfections and infestations5/654/128
Abdominal painGastrointestinal disorders1/659/128
Abdominal distensionGastrointestinal disorders2/658/128
NauseaGastrointestinal disorders3/658/128
FatigueGeneral disorders4/658/128

Baseline characteristics

The Safety Analysis Set was defined as any participant who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)PlaceboSeladelparTotal
<=18 years000
Between 18 and 65 years5399152
>=65 years122941
Age, Continuous
Age, Continuous(years)PlaceboSeladelparTotal
Mean57 ± 9.257 ± 10.057 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSeladelparTotal
Female60123183
Male5510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboSeladelparTotal
Hispanic or Latino272956
Not Hispanic or Latino3897135
Unknown or Not Reported022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboSeladelparTotal
American Indian or Alaska Native336
Asian4711
Native Hawaiian or Other Pacific Islander000
Black or African American224
White56114170
More than one race000
Unknown or Not Reported022
Region of Enrollment
Region of Enrollment(Participants)PlaceboSeladelparTotal
United States134861
Argentina131629
Mexico6612
Spain4711
Russia189
Italy448
Turkey178
United Kingdom268
Poland527
South Korea347
Israel235
Belgium213
Czechia123
Switzerland213
Australia112
Canada022
Chile022
France022
Germany112
Greece202
Hungary022
New Zealand202
Romania022
Austria011
Pruritus Numerical Rating Scale (NRS) for Participants With Baseline Pruritus NRS ≥ 4
Pruritus Numerical Rating Scale (NRS) for Participants With Baseline Pruritus NRS ≥ 4(score on a scale)PlaceboSeladelparTotal
Mean6.6 ± 1.446.1 ± 1.426.3 ± 1.43
Alkaline Phosphatase (ALP) Levels
Alkaline Phosphatase (ALP) Levels(U/L)PlaceboSeladelparTotal
Mean313.8 ± 117.68314.6 ± 122.96314.3 ± 120.90
08

Study locations

134 sites
  • The Institute for Liver Health DBA Arizona Liver Health
    Chandler, Arizona 85224, United States
  • Arkansas Diagnostic Center
    Little Rock, Arkansas 72205, United States
  • Stanford University School of Medicine
    Palo Alto, California 94305, United States
  • California Liver Research Institute
    Pasadena, California 91105, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • California Pacific Medical Center - Sutter Pacific Medical Foundation
    San Francisco, California 94109, United States
  • Covenant Metabolic Specialists, LLC
    Fort Myers, Florida 33912, United States
  • Florida Research Institute
    Lakewood Ranch, Florida 34211, United States
  • Schiff Center for Liver Diseases/University of Miami
    Miami, Florida 33136, United States
  • Covenant Research and Clinics, LLC
    Sarasota, Florida 34240, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago Hospitals
    Chicago, Illinois 60637, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Henry Ford Health System
    Novi, Michigan 48377, United States
  • MNGI Digestive Health, P.A.
    Maplewood, Minnesota 55117, United States
  • Southern Therapy and Advanced Research, LLC (STAR)
    Jackson, Mississippi 39216, United States
  • Saint Louis University
    Saint Louis, Missouri 63104, United States
  • NYU Langone Health / NYU Grossman School of Medicine
    New York, New York 10016, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Care Access Research - Lumberton
    Lumberton, North Carolina 28358, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Penn State Milton S Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • UPMC Center for Liver Diseases
    Pittsburgh, Pennsylvania 15213, United States
  • Galen Hepatology
    Chattanooga, Tennessee 37421, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Vanderbilt Digestive Disease Center
    Nashville, Tennessee 37212, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Texas Digestive Disease Consultants dba GI Alliance
    Fort Hood, Texas 76104, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • American Research Corporation at the Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research, PLLC
    San Antonio, Texas 78229, United States
  • Bon Secours Richmond Community Hospital LLC
    Richmond, Virginia 23226, United States
  • Liver Institute Northwest
    Seattle, Washington 98105, United States
  • Centro Medico Dra. De Salvo
    Caba, Buenos Aires C1426ABP, Argentina
  • STAT Research S.A.
    Ciudad Autonoma de Buenos Aire, Buenos Aires C1023AAB, Argentina
  • Hospital Italiano de La Plata
    La Plata, Buenos Aires B1900AX, Argentina
  • DIM CliniaPrivada
    Ramos Mejía, Buenos Aires B1704ETD, Argentina
  • CINME (Centro de Investigaciones Metabolicas)
    Buenos Aires, C1056ABJ, Argentina
  • Hospital Italiano de Buenos Aires
    Caba, C1199ABB, Argentina
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Royal Brisbane & Women's Hospital
    Herston, Queensland 4029, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Klinikum Wels-Grieskirchen GmbH, Abteilung Fur Innere Medizin I - Gastroenterologie
    Wels, 4600, Austria
  • UZ Antwerpen
    Edegem, Antwerpen 2650, Belgium
  • CHU de Liège
    Liege, Liège 4000, Belgium
  • AZ Maria Middelares
    Gent, Oost-Vlaanderen 9000, Belgium
  • Universitair Ziekenhuis Gent
    Gent, Oost-Vlaanderen 9000, Belgium
  • Universitaire Ziekenhuizen Leuven
    Leuven, Vlaams-Brabant 3000, Belgium
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
  • University Health Network
    Toronto, Ontario M5G 2C4, Canada
  • Toronto Digestive Disease Associates Inc
    Vaughan, Ontario L4L 4Y7, Canada
  • Centro Clinico Mediterraneo
    La Serena, Coquimbo 1700000, Chile
  • Clinical Research Chile SpA
    Valdivia, Los Ríos 5110683, Chile
  • Centro de Investigaciones Clínicas Vina del Mar
    Valparaíso, 2540364, Chile
  • Fakultni nemocnice Ostrava- Interni a Kardiologicka Klinika, Oddeleni gastroenterologie, hepatologie a pankreatologie
    Ostrava, 708 52, Czechia
  • Aalborg Universitetshospital, Ambulatoriet for Medicinske Mave-Tarm Sygdomme
    Aalborg, 9000, Denmark
  • Hvidovre Hospital
    Hvidovre, 2650, Denmark
  • CHU de Grenoble
    Grenoble, 38043, France
  • Hopital de la Croix-Rousse
    Lyon, 69004, France
  • Hopital Saint-Antoine - Service d'Hepato-Gastro-Enterologie -184, rue du Faubourg Saint-Antoine
    Paris, 75012, France
  • Universitätsklinikum Bonn
    Bonn, Nordrhein-Westfalen 53127, Germany
  • Universitätsklinikum des Saarlandes
    Homburg, Saarland 66421, Germany
  • Universitatsklinikum Erlangen, Medizinische Klinik I, Gastroenterologie
    Erlangen, 91054, Germany
  • Universitatsklinikum Frankfurt. Medizinische Klinik I
    Frankfurt am main, 60590, Germany
  • Ifi-Medizin GmbH
    Hamburg, 20099, Germany
  • Gastroenterologische Gemeinschaftspraxis
    Herne, 44623, Germany
  • Universitatsklinikum Leipzig
    Leipzig, 04103, Germany
  • Ippokrateio General Hospital of Athens
    Athens, Attiki 115 27, Greece
  • General University Hospital of Larissa Department of Medicine and Research Laboratory of internal rv1edicine, National Expertise Center of Greece in Autoimmune liver Diseases
    Larissa, 41110, Greece
  • Semmelweis Egyetem
    Budapest, 1082, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz
    Kaposvár, 7400, Hungary
  • Liver Unit
    Jerusalem, 91120, Israel
  • Liver Disease Center, Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Institute for Digestive Tract & Liver Disease
    Tel Aviv, 64239, Israel
  • ASST di Monza
    Monza, MB 20900, Italy
  • Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona-Umberto I G.M. Lancisi G. Salesi
    Ancona, 60020, Italy
  • Nuovo Ospedale Civile S. Agostino-Estense di Baggiovara
    Bologna, 41126, Italy
  • Azienda Ospedaliero Universitaria Careggi
    Firenze, 50139, Italy
  • Azienda Ospedaliera Universita Padova
    Padova, 35128, Italy
  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
    Palermo, 90127, Italy
  • Inje University Busan Paik Hospital
    Busan, Busan Gwangyeogsi 47392, Korea, Republic of
  • Soon Chun Hyang University Hospital Bucheon
    Bucheon-si, Gyeonggido 14584, Korea, Republic of
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, 41944, Korea, Republic of
  • Seoul National University Bundang Hospital
    Gyeonggi-do, 13620, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Severance Hospital Yonsei University Health System - PPDS
    Soeul, 03722, Korea, Republic of
  • Consultorio Medico - Distrito Federal
    Ciudad de Mexico, 06700, Mexico
  • Consultorio de la Doctora Maria Sarai Gonzalez Huezo
    Metepec, 52140, Mexico
  • Campeche No. 280, Int. 601 y 602, Col. Hipodromo, Cuauhtemoc
    Mexico City, 06100, Mexico

Showing the first 100 of 134 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Aug 2023, 27 months.

Results were first posted in Jul 2024, 11 months after primary completion. A results delay was requested in Sep 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2020
First posted
Nov 9, 2020
StartActual
Apr 21, 2021
Primary completionActual
Aug 11, 2023
CompletionActual
Aug 11, 2023
Results delay requested
Sep 26, 2023
Results first posted
Jul 25, 2024
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04620733
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 9, 2020
Start date
Apr 21, 2021
Primary completion
Aug 11, 2023
Completion
Aug 11, 2023
Results posted
Jul 25, 2024
Last update
Sep 5, 2024

Study contacts

CymaBay Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seladelpar

Start the discussion